Marco Demaria obtained his PhD at the University of Torino, Italy, under the supervision of prof. Valeria Poli. In Poli’s lab, he characterized the role of the transcription factor STAT3 as a master regulator of cancer cell survival and metabolism. He joined the laboratory of prof. Judith Campisi at the Buck Institute for Research on Aging, California USA, in the summer of 2010 to navigate through the complex phenotypes of senescent cells. He also started to be interested in therapeutic approaches to target the negative aspect of senescent cells. He joined the University of Groningen and the European Research Institute for the Biology of Aging (ERIBA) in September 2015 as an Assistant Professor and Group leader of the laboratory “Cellular Senescence and Age-related Pathologies”. His research is focused towards understanding the cell non-autonomous functions of senescent cells, including their roles in inflammation. The goal of his research group is to dissect positive and negative roles of cellular senescence in different physiological and pathological context. His laboratory is funded by several intramural and extramrual agencies. In 2018 he co-founded a start-up company, Cleara Biotech, devoted to develop anti-senescence drugs. Dr Demaria also serves as academic editor for Scientific Reports and Plos One.